Bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized in the US. This Clinical Advisory on monovalent vaccines contains information on recommendations, ordering information, documentation, additional resources, and more.
Influenza and Adult Immunization Guide Updated for 2023-24
On August 24, 2023, PharMerica released its 2023-2024 Influenza and Adult Immunization Guide! Inside, you'll find materials covering clinical and regulatory issues with respect to influenza and other select vaccine-preventable diseases, including:
CMS requirements for influenza, pneumococcal, and COVID-19 vaccines
CDC guidance on influenza vaccines, antivirals, and managing outbreaks
Updated recommendations for influenza, pneumococcal, hepatitis B, and shingles vaccines
Recommendations for the two recently approved RSV vaccines
Essential documents for facility use such as Vaccine Information Statements (VIS), consent forms, and declination forms
Onco360 Offers Recently Approved Momelotinib (Ojjaara) for Myelofibrosis
Onco360 has been selected by GlaxoSmithKline to be a specialty pharmacy network partner for momelotinib (Ojjaara). Ojjaara was approved by the FDA on 9/15/2023 for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
Changes to MDS 3.0-1.18.11 took effect on October 1, 2023, and will influence PDPM rate calculations and other issues that impact reimbursement and compliance. These resources — a comprehensive guide that reviews key updates and a Compliance Cue focused on high-risk drugs in Section N — will help you and your staff understand what's new.
Medicare Billing Guidance for Respiratory Vaccines in LTC
This guide, released by AHCA/NCAL as part of their 2023 #GetVaccinated toolkit, summarizes Medicare billing issues for the influenza, COVID, RSV, and pneumococcal vaccines.
